Skip to main content
Loading page, please wait…
HomeCurrent AffairsEditorialsGovt SchemesLearning ResourcesUPSC SyllabusPricingAboutUPSC AI ToolsUPSC AI ToolAI for UPSCUPSC ChatGPT

© 2026 Vaidra. All rights reserved.

PrivacyTerms
Vaidra Logo
Vaidra

Top 4 items + smart groups

UPSC GPT
New
Current Affairs
Daily Solutions
Daily Puzzle
Mains Evaluator

Version 2.0.0 • Built with ❤️ for UPSC aspirants

Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...

Delhi High Court Refuses Stay on HPV Vaccination Drive – Legal and Health Policy Implications

On 29 July 2026, the Delhi High Court declined to halt the HPV vaccination drive for 14‑year‑old girls, finding no immediate safety evidence. The court ordered the Centre, CDSCO and ICMR to submit detailed replies, underscoring the need for strict protocol compliance and informed consent in public‑health initiatives.
The Delhi High Court on 29 July 2026 rejected a petition to halt the central government's ongoing HPV vaccine programme for 14‑year‑old girls. The bench said the material before it did not show any immediate harm and that the vaccine is not part of the Universal Immunisation Programme. Key Developments The bench comprising Chief Justice D.K. Upadhyaya and Justice Tejas Karia observed that the data on 5.5 million doses administered showed no "instant harm". The court warned against "half‑baked vaccines" and stressed strict adherence to protocols. It directed the Centre, the CDSCO and the ICMR to file separate replies within four weeks. The petition, filed as a PIL , raised concerns over long‑term safety, informed consent and adverse‑event monitoring. Important Facts According to the Additional Solicitor General Chetan Sharma, as of 25 July 2026, 5.5 million doses had been given, with 120 adverse‑event reports. Of these, 42 were "slightly aggravated" symptoms and no deaths were recorded. The programme, launched on 28 February 2026, is voluntary and requires prior informed consent from parents. The petitioners cited international safety concerns about the brand Gardasil and a specific case from Tamil Nadu where a girl reportedly developed severe neurological symptoms within days of vaccination. UPSC Relevance This case touches upon several GS topics: public health policy (preventive vaccination, conse
Loading article...

Quick Reference

Key Insight

Delhi HC backs HPV drive, stressing safety data and policy urgency

Key Facts

  1. 29 July 2026: Delhi High Court ने HPV vaccine programme पर रोक की मांग करने वाले PIL को खारिज किया।
  2. यह programme 28 February 2026 को शुरू हुआ और यह माता‑पिता की सूचित सहमति के साथ स्वैच्छिक है।
  3. 25 July 2026 तक 5.5 million डोज़ दी जा चुकी हैं; 120 प्रतिकूल‑घटना रिपोर्टें, 42 हल्की, कोई मृत्यु नहीं।
  4. वैक्सीन (Gardasil) Universal Immunisation Programme का हिस्सा नहीं है।
  5. अदालत ने केंद्र, CDSCO और ICMR को चार हफ्तों के भीतर विस्तृत उत्तर प्रस्तुत करने को कहा।
  6. CDSCO वह राष्ट्रीय प्राधिकरण है जो दवाओं और वैक्सीनों को मंजूरी देता और निगरानी करता है।
  7. ICMR स्वास्थ्य programmes के लिए दिशानिर्देश बनाता है और वैक्सीनों पर अनुसंधान करता है।

Background

The case links health policy with constitutional law. It shows how courts can review executive health actions while ensuring safety monitoring by regulatory bodies like CDSCO and ICMR. The issue fits under public‑health governance, judicial review and the separation of powers in the UPSC syllabus.

UPSC Syllabus

  • GS2 — Executive and Judiciary - structure, organization and functioning
  • Prelims_GS — Biology and Health
  • Prelims_GS — Public Policy and Rights Issues
  • Essay — Democracy, Governance and Public Administration

Mains Angle

In Mains, this can be used for GS‑3 questions on health governance and judicial oversight. A possible question may ask to evaluate the role of courts in balancing rapid vaccination drives with safety concerns.

Explore:Current Affairs·Editorial Analysis·Govt Schemes·Study Materials·Previous Year Questions·UPSC GPT
  1. Home
  2. Prepare
  3. Current Affairs
  4. Society
  5. Education & Health Initiatives
  6. Delhi High Court Refuses Stay on HPV Vaccination Drive – Legal and Health Policy Implications
GS382% Exam RelevanceEducation & Health Initiatives
Must Review
Login to bookmark articles
Login to mark articles as complete

Overview

Full Article

The Delhi High Court on 29 July 2026 rejected a petition to halt the central government's ongoing HPV vaccine programme for 14‑year‑old girls. The bench said the material before it did not show any immediate harm and that the vaccine is not part of the Universal Immunisation Programme.

Key Developments

  • The bench comprising Chief Justice D.K. Upadhyaya and Justice Tejas Karia observed that the data on 5.5 million doses administered showed no "instant harm".
  • The court warned against "half‑baked vaccines" and stressed strict adherence to protocols.
  • It directed the Centre, the CDSCO and the ICMR to file separate replies within four weeks.
  • The petition, filed as a PIL, raised concerns over long‑term safety, informed consent and adverse‑event monitoring.

Important Facts

According to the Additional Solicitor General Chetan Sharma, as of 25 July 2026, 5.5 million doses had been given, with 120 adverse‑event reports. Of these, 42 were "slightly aggravated" symptoms and no deaths were recorded. The programme, launched on 28 February 2026, is voluntary and requires prior informed consent from parents.

The petitioners cited international safety concerns about the brand Gardasil and a specific case from Tamil Nadu where a girl reportedly developed severe neurological symptoms within days of vaccination.

Exam Relevance

This case touches upon several GS topics: public health policy (preventive vaccination, conse

Read Original on hindu

Delhi HC backs HPV drive, stressing safety data and policy urgency

Key Facts

  1. 29 July 2026: Delhi High Court ने HPV vaccine programme पर रोक की मांग करने वाले PIL को खारिज किया।
  2. यह programme 28 February 2026 को शुरू हुआ और यह माता‑पिता की सूचित सहमति के साथ स्वैच्छिक है।
  3. 25 July 2026 तक 5.5 million डोज़ दी जा चुकी हैं; 120 प्रतिकूल‑घटना रिपोर्टें, 42 हल्की, कोई मृत्यु नहीं।
  4. वैक्सीन (Gardasil) Universal Immunisation Programme का हिस्सा नहीं है।
  5. अदालत ने केंद्र, CDSCO और ICMR को चार हफ्तों के भीतर विस्तृत उत्तर प्रस्तुत करने को कहा।
  6. CDSCO वह राष्ट्रीय प्राधिकरण है जो दवाओं और वैक्सीनों को मंजूरी देता और निगरानी करता है।
  7. ICMR स्वास्थ्य programmes के लिए दिशानिर्देश बनाता है और वैक्सीनों पर अनुसंधान करता है।

Background & Context

The case links health policy with constitutional law. It shows how courts can review executive health actions while ensuring safety monitoring by regulatory bodies like CDSCO and ICMR. The issue fits under public‑health governance, judicial review and the separation of powers in the UPSC syllabus.

UPSC Syllabus Connections

GS2•Executive and Judiciary - structure, organization and functioningPrelims_GS•Biology and HealthPrelims_GS•Public Policy and Rights IssuesEssay•Democracy, Governance and Public Administration

Mains Answer Angle

In Mains, this can be used for GS‑3 questions on health governance and judicial oversight. A possible question may ask to evaluate the role of courts in balancing rapid vaccination drives with safety concerns.

Analysis

Related PYQs

No related PYQs linked to this article yet.

Practice Questions

GS2
Easy
Prelims MCQ

Regulatory oversight of health programmes

2 marks
3 keywords
GS3
Medium
Mains Short Answer

Public health policy and judicial review

10 marks
6 keywords
GS3
Hard
Mains Essay

Governance of preventive health programmes

250 marks
6 keywords
Related:Daily•Weekly

Loading related articles...

Loading related articles...

Tip: Click articles above to read more from the same date, or use the back button to see all articles.